Orexigen(R) Therapeutics Announces Changes To Its Clinical Programs And Management Team Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX) announced changes to conserve the Company's resources, focus its efforts on its late-stage obesity programs and realign its management team.
Source: www.medicalnewstoday.comRHEI Pharmaceuticals Announces The Initiation Of The Final Clinical Study For Approval Of Tibozole In China RHEI Pharmaceuticals, Inc. announced that the final clinical trial for Tibozole, a locally active antifungal with low dose miconazole in a patented mucoadhesive system, has been initiated in China. This will be the last clinical trial conducted for submission of the New Drug Application (NDA) to the State Food and Drug Administration (SFDA) in China. RHEI licensed Tibozole from Tibotec, a Johnson and Johnson company.
Source: www.medicalnewstoday.comBayer Announces Upcoming Presentations Of Campath(R) And Leukine(R) Data At The 50th Annual Meeting Of The American Society Of Hematology Bayer
HealthCare Pharmaceuticals Inc. announced that data on Campath(R) (alemtuzumab) and Leukine(R) (sargramostim) will be presented at the 50th Annual Meeting of the American Society of Hematology (ASH) from December 6-9, 2008 in San Francisco, California.
Source: www.medicalnewstoday.comWyeth Submits European Marketing Authorization Application For Its 13-Valent Vaccine For The Prevention Of Pneumococcal Disease Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), announced that it has submitted a marketing authorization application (MAA) to the European
Medicines Agency (EMEA) for approval to market its investigational 13-valent pneumococcal conjugate vaccine (PCV13) for infants and young children.
Source: www.medicalnewstoday.comGenVec Announces Multiple Presentations At The American Society Of Tropical Medicine And Hygiene Meeting GenVec, Inc. (Nasdaq: GNVC) announced that the company will present on GenVec's malaria vaccine program at the American Society of Tropical
Medicine and Hygiene (ASTMH) 57th Annual Meeting, which will take place in New Orleans, LA on December 7-11, 2008. Two presentations, highlighting research conducted in this program, will be given by GenVec scientists.
Source: www.medicalnewstoday.comNew Data Suggest CIMZIA(R) (Certolizumab Pegol) Active in Treating Moderate to Severe Crohn's Patients With Fistulizing Disease Data presented this week by UCB at Advances in Inflammatory Bowel Diseases 2008, the Crohn's & Colitis Foundation's Clinical & Research Conference, demonstrated more than half (53.6%) of those moderate to severe Crohn's disease patients who had open fistulas at baseline had closure of fistulas by Week 26 following short-term induction therapy with CIMZIA(R) (certolizumab pegol) - the only PEGylated anti-TNFa (Tumor Necrosis Factor alpha).
Source: www.medicalnewstoday.com
# posted by Network @ 7:00 AM
